ストックスクリーナーアプリを入手
2.13
2.29%
-0.05
アフターアワーズ：
2.10
-0.03
-1.41%
Icecure Medical Ltd (ICCM) 最新ニュース
IceCure Medical (ICCM) Falls Over 11%: Key Support Levels Tested After Sharp DeclineCall Resistance - newsline.com
Icecure Medical Analyst Ratings and Price Targets | NASDAQ:ICCM - Benzinga
IceCure Medical to boost share price with 1-for-30 reverse split to regain NASDAQ compliance - MSN
IceCure Medical announces reverse share split - Medical Buyer
IceCure Medical (ICCM) Announces 1-for-30 Reverse Stock Split to Meet Nasdaq Requirements - GuruFocus
IceCure Medical: Split Part of Co's Proactive Efforts to Regain Compliance With Nasdaq $1 Minimum Bid Price Requirement and Support Co's Broader Cap Markets Strategy >ICCM - Moomoo
IceCure Medical (ICCM) Announces 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing - GuruFocus
IceCure Medical Announces 1-for-30 Reverse Share Split to Maintain Nasdaq Listing - geneonline.com
IceCure Stock Drops Before The Bell As Nasdaq’s $1 Clock Ticks - Bez Kabli
IceCure Medical (NASDAQ: ICCM) implements 1-for-30 reverse share split for Nasdaq - Stock Titan
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance - PR Newswire
IceCure Medical Enacts 1-for-30 Reverse Share Split to Bolster Nasdaq Compliance - TipRanks
Why Has IceCure Medical's Stock Price Collapsed - Kavout
Number of shareholders of IceCure Medical Ltd. – BOATS:ICCM - TradingView
IceCure Medical (ICCM) Retreats Toward Support After 4% DeclineFair Value Gap - newsline.com
IceCure Medical (ICCM) Edges Higher as Stock Tests Key Resistance Near $0.24Advance Decline Volume - The Legal Advocate
Icecure Medical Earnings Call Highlights Growth Momentum - The Globe and Mail
Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Rob - GuruFocus
IceCure Medical presents positive ProSense cryoablation data - grafa.com
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for - GuruFocus
IceCure Showcases Strong ProSense® Cryoablation Data and Surge in Clinical Interest at ECIO 2026 - TipRanks
IceCure Medical (ICCM) highlights kidney and breast cryoablation data at ECIO 2026 - Stock Titan
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked - PR Newswire
[Form 4] IceCure Medical Ltd. Insider Trading Activity - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (ICCM) CFO reports 400,000 RSUs equity grant - Stock Titan
IceCure Medical Ltd. (ICCM) reports Q1 loss, lags revenue estimates - MSN
IceCure Medical Ltd.Ordinary Shares (NQ: ICCM - The Chronicle-Journal
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Cuts Target Price to $1 - Moomoo
ICCM Maintained by Maxim Group -- Price Target Lowered to $1.00 - GuruFocus
IceCure Medical Wins Nasdaq Extension to Restore Minimum Bid Compliance - The Globe and Mail
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - The Malaysian Reserve
Icecure granted 180-day extension by Nasdaq to regain compliance with minimum bid requirement - marketscreener.com
IceCure Medical (ICCM) wins new 180-day window to meet Nasdaq $1 bid - Stock Titan
IceCure Medical Ltd (NASDAQ:ICCM) Q1 2026 Earnings Call Transcript - Insider Monkey
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America - StreetInsider
ICECURE MEDICAL ($ICCM) Releases Q1 2026 Earnings - Moomoo
[424B5] IceCure Medical Ltd. Prospectus Supplement (Debt Securities) - Stock Titan
IceCure Medical Sets Up At-the-Market Equity Program With A.G.P./Alliance Global Partners - TipRanks
[6-K] IceCure Medical Ltd. Current Report (Foreign Issuer) | ICCM SEC FilingForm 6-K - Stock Titan
ICCM: Strong Q1 Revenue Growth Signals Positive Market Momentum - GuruFocus
IceCure (ICCM) Q1 2026 Earnings Transcript - AOL.com
IceCure Reports First Quarter 2026 Financial Results: ProSense® - GuruFocus
ICCM: Q1 2026 revenue up 26% year-over-year, driven by U.S. growth and post-FDA commercial momentum - TradingView
ICCM: Q1 2026 saw 26% revenue growth and accelerating U.S. adoption following FDA clearance - TradingView
1.21%
1.43%
大文字化:
|
ボリューム (24 時間):